staurosporine has been researched along with lapatinib in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K | 1 |
| Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
| Cheng, T; Ge, Z; Li, R; Li, Y; Lin, S; Luo, L; Sun, Q; Zheng, Y | 1 |
| Abouzid, KAM; Esmat, A; Hossam, M; Ismail, NSM; Lasheen, DS; Mansour, AM; Singab, ANB | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Abdel-Maksoud, MS; Alach, NN; Anbar, HS; El-Gamal, MI; El-Gamal, R; Oh, CH; Sbenati, RM; Shehata, MK; Tarazi, H; Zaraei, SO | 1 |
| Abd Elaziz, MR; Abdelrahman, BA; Abdou, AM; Ahmed, EY; El-Mansy, MF; Elsayed, KH; Elserwy, WS; Salem, AM; Serry, AM | 1 |
| Marais, R; Niculescu-Duvaz, D; Springer, C; Whittaker, S | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
15 other study(ies) available for staurosporine and lapatinib
| Article | Year |
|---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Phosphoramide Mustards; Quinazolines; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2017 |
Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Imidazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, ErbB-4; Structure-Activity Relationship; Thiazoles | 2021 |
Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Growth Inhibitors; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
The EGF receptor Hokey-Cokey.
Topics: Antineoplastic Agents; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |